# Dynamic Changes in Oxidative Stress Biomarkers in a Child with Idiopathic Nephrotic Syndrome: A Longitudinal Case Study

## TL;DR

This study tracks oxidative stress in a child with kidney disease over a year, showing how it changes with treatment and illness activity.

## Contribution

The study demonstrates dynamic redox biomarkers in a pediatric nephrotic syndrome case, suggesting their potential for monitoring disease and treatment.

## Key findings

- Oxidative stress biomarkers fluctuated with disease relapses and remissions.
- Antioxidant defense improved during remission and worsened during relapses.
- Biomarker changes correlated with glucocorticoid treatment and disease activity.

## Abstract

Idiopathic nephrotic syndrome (INS) is the most prevalent glomerular illness in children. Even while immunologic processes are well-established, oxidative stress is becoming more widely acknowledged as a significant factor in the etiopathogenesis of illness. Assessing its activity and treatment response may be made easier with the use of trustworthy, non-invasive indicators to track redox balance. We report on the oxidative stress levels of a 10.7-year-old boy with INS with five clinical time points in one year. The FRAS5 analyzer was used to calculate the oxidative stress index (OSI), plasma antioxidant capacity (PAT) and derivatives of reactive oxygen metabolites (d-ROMs) as biomarkers. A 4-tier oxidative state classification scheme based on d-ROM and PAT thresholds was used to interpret the values. The patient had low antioxidant defense, moderate oxidative and increased OSI at relapses, a positive transition to reduced oxidative burden and enhanced defense during remission. The order of events showed a dynamic redox response associated with glucocorticoid (GC) medication and disease activity. The potential value of d-ROM, PAT, and OSI as dynamic biomarkers for tracking disease activity, response to treatment and residual oxidative burden in pediatric INS is supported by this case. To confirm their function in more comprehensive clinical decision-making, more research is required.